HMGB1 and polycystic ovary syndrome: In our previous study [28], we also demonstrated the efficacy of CRY in the treatment of PCOS and proposed that its mode of action is mediated by its effect on the regulation of the HMGB1/TLR4/NF-kappaB signaling pathway.